Blackstone 将为 Moderna 的流感研究提供高达 7.5 亿美元的资助。 Blackstone to Fund Moderna's Flu Research With up to $750 Million.

Moderna 已从 Blackstone Life Sciences 获得 7.5 亿美元投资，用于开发 mRNA 流感疫苗。 Moderna has secured a $750m investment from Blackstone Life Sciences to develop its mRNA flu vaccines. 这家生物技术公司计划在 2024 年斥资 45 亿美元用于研发，目标是开发多种疫苗，以弥补新冠疫苗销量下降的影响。 The biotech firm plans to spend $4.5bn on research and development in 2024 as it aims to develop multiple vaccines to compensate for the decline in sales of its COVID shots. 作为协议的一部分，Blackstone Life Sciences 将获得商业里程碑付款和低个位数的特许权使用费。 Blackstone Life Sciences will receive commercial milestone payments and low-single digit royalties as part of the agreement.